{"id":981925,"date":"2026-07-15T16:05:06","date_gmt":"2026-07-15T20:05:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/"},"modified":"2026-07-15T16:05:06","modified_gmt":"2026-07-15T20:05:06","slug":"ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/","title":{"rendered":"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS"},"content":{"rendered":"
\n

SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) — Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS<\/strong>) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target.<\/p>\n

The surprise result and severe market reaction have prompted national shareholders\u2019 rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial\u2019s data and design and, if not, whether the company may have violated the federal securities laws. The firm encourages Ionis investors who suffered substantial losses to submit your losses now<\/strong><\/a>.<\/p>\n

\n Visit:<\/strong>
\n www.hbsslaw.com\/investor-fraud\/ions<\/a>
\n
\n Contact the Firm Now: <\/strong>
\n IONS@hbsslaw.com<\/a>
\n
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0844-916-0895<\/p>\n

\n Ionis Pharmaceuticals, Inc. (IONS) Investigation:<\/strong>\n <\/p>\n

The investigation is focused on Ionis\u2019 statements regarding the development of eplontersen, a medicine intended to treat patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM. The company completed enrollment in the Phase 3 CARDIO-TTRansform study in July 2023.<\/p>\n

Just last month, Ionis touted the Phase 3 study as \u201cthe largest study ever conducted by far\u201d in ATTR-CM , setting the company up \u201cfor the richest dataset for not only the primary endpoint, but the secondary endpoints[.]\u201d Ionis also assured investors that \u201ceverything is going very well in the conduct of the study and execution.\u201d<\/p>\n

Investors\u2019 expectations were dashed on July 9, 2026 when Ionis announced that the Phase 3 CARDIO-TTRansform trial did not meet the primary efficacy endpoint \u2013 \u201c[i]n this contemporary patient population treated with standard of care, including a majority on a stabilizer, adding eplontersen did not provide a statistically significant benefit.\u201d The company further revealed that \u201c57% of patients in each arm received a stabilizer treatment at baseline, and a further 24% in each arm initiated a stabilizer during the trial.\u201d<\/p>\n

In response, the market swiftly reacted by wiping out over $3.3 billion of Ionis\u2019 market capitalization.<\/p>\n

In addition, one prominent analyst reportedly wrote \u201cUnbeknownst to us, > 80% of CARDIO-TTRansform participants were on stabilizer [\u2026] driving the failure of the primary endpoint[.]\u201d<\/p>\n

\u201cOur investigation is focused on when Ionis and its management first knew about the apparent problems with the trial data or its design and whether they were sufficiently transparent to investors,\u201d said Reed Kathrein<\/strong><\/a>, the Hagens Berman partner leading the firm\u2019s investigation.<\/p>\n

If you invested in Ionis and have substantial losses, or have knowledge that will assist the firm\u2019s investigation, submit your losses now<\/a> \u00bb<\/p>\n

If you\u2019d like more information and answers to other frequently asked questions about the firm\u2019s Ionis investigation, read more<\/a> \u00bb<\/p>\n

\n Whistleblowers: <\/strong>Persons with non-public information regarding Ionis should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895<\/strong> or email IONS@hbsslaw.com<\/a>.<\/p>\n

\n About Hagens Berman<\/a>
\n
Hagens Berman is a global plaintiffs\u2019 rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman\u2019s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0@ClassActionLaw<\/a>.\u00a0<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.<\/p>\n

\n Contact: <\/u>
\n
Reed Kathrein, 844-916-0895<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) — Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders\u2019 rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial\u2019s data and design and, if not, whether the company may have violated the federal securities laws. The firm encourages Ionis investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com\/investor-fraud\/ions Contact the Firm Now: IONS@hbsslaw.com \u00a0 … <\/p>\n

Continue reading “Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-981925","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) — Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders\u2019 rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial\u2019s data and design and, if not, whether the company may have violated the federal securities laws. The firm encourages Ionis investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com\/investor-fraud\/ions Contact the Firm Now: IONS@hbsslaw.com \u00a0 … Continue reading "Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T20:05:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS\",\"datePublished\":\"2026-07-15T20:05:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/\"},\"wordCount\":600,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/\",\"name\":\"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=\",\"datePublished\":\"2026-07-15T20:05:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/","og_locale":"en_US","og_type":"article","og_title":"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS - Market Newsdesk","og_description":"SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) — Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders\u2019 rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial\u2019s data and design and, if not, whether the company may have violated the federal securities laws. The firm encourages Ionis investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com\/investor-fraud\/ions Contact the Firm Now: IONS@hbsslaw.com \u00a0 … Continue reading \"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-15T20:05:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS","datePublished":"2026-07-15T20:05:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/"},"wordCount":600,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/","name":"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=","datePublished":"2026-07-15T20:05:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzAxMSM3NzA4NTEwIzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-pharmaceuticals-inc-ions-faces-investor-scrutiny-after-surprise-trial-failure-drives-stock-down-23-hbss-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=981925"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981925\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=981925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=981925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=981925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}